Home

Morana Jovan-Embiricos

CIK 1575745 · last filed 2026-06-04

Morana Jovan-Embiricos is a corporate insider who has filed 23 SEC Form 4 insider transactions across 5 companies since 2014. The most recent filing, for KLRS, was dated Jun 4, 2026. Across all open-market trades the lifetime net is +$37.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $9.8M across reported positions. 8 SEC filings were submitted jointly with F2 MG Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$9.75M

Companies

5

Total Filings

23

Lifetime Open-Market Net

$37.47M

Filer Profile

Reported Address
C/O RADIUS HEALTH, INC.
201 BROADWAY, 6TH FLOOR
BOSTON, MA 02139
Related Filers
F2 MG Ltd — 8 joint filings, latest 2021-01-14
Globeways Holdings Ltd — 8 joint filings, latest 2021-01-14
Globeways Holdings II Ltd — 6 joint filings, latest 2019-12-20
Vision SCS F2 — 5 joint filings, latest 2022-08-04
F2 Capital I 2019, LLC — 4 joint filings, latest 2019-12-20
F2 BBG LLC — 3 joint filings, latest 2019-12-20
F2 Bio TD, LLC — 2 joint filings, latest 2021-01-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KLRS Director — $3.12 — $0 2 2026-06-04
Kalaris Therapeutics, Inc. (ALVR) Delisted Director 42,081 $9.81 $412.8K $48.59M 11 2024-06-07
CGEM Director 578,214 $16.87 $9.75M -$10.70M 4 2022-06-28
TCR2 THERAPEUTICS INC. (TCRR) Delisted 10%+ Owner 90,026 $1.48 $133.2K -$412.5K 1 2019-10-24
Radius Health, Inc. (RDUS) Delisted Director 0 $30.00 $0 $0 5 2015-01-20

Recent Filings

23 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-04 KLRS Grant (A) — $0 EDGAR
2025-04-11 KLRS Grant (A) — $0 EDGAR
2024-06-07 Kalaris Therapeutics, Inc. (ALVR) Delisted Grant (A) +35,000 $0 EDGAR
2023-05-12 Kalaris Therapeutics, Inc. (ALVR) Delisted Grant (A) +35,000 $0 EDGAR
2022-08-01 Kalaris Therapeutics, Inc. (ALVR) Delisted Grant (A) +8,152,247 $37.58M EDGAR
2022-06-28 CGEM Mixed +95,296 $14 EDGAR
2022-06-23 CGEM Sell (S) −203,806 -$2.61M EDGAR
2022-05-19 Kalaris Therapeutics, Inc. (ALVR) Delisted Grant (A) — $0 EDGAR
2022-05-16 CGEM Sell (S) −837,476 -$8.09M EDGAR
2022-03-25 CGEM Grant (A) — $0 EDGAR
Showing 1–10 of 23
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.